Paracelsus Medical University (PMU)

Nano vesicular therapies

Director // Univ.-Doz. Dr. Mario Gimona

The research programme aims to develop biological drugs from stem cells. The aim is to establish this innovative and forward-looking field of research at Paracelsus University. Cell-free biological drugs are developed using stem and precursor cells.

Research

Research is underway on a promising method to enhancethe body’s natural healing processeswithout the need for live cell transplants. Adult human stem and progenitor cells play a key role in this approach. These cells can be grown outside the body and then transformed into different cell types.

Studies have shown that these cells have positive effects on bone growth, cell differentiation, and other healing processes, even without permanently integrating into the affected tissue. Instead of replacing tissue directly, they stimulate surrounding cells to initiate self-repair.

The focus of the research is on the extracellular vesicles (eNV) released by these cells.  These tiny, round to oval-shaped bubbles, measuring just 70-120 nanometers, can mimic the healing effects of the cells. Using these vesicles as a biological therapy could reduce the need for live cell transplants and lower the risk of tumor formation.

When applied in various therapies, these vesicles could, for example, enhance the body’s natural repair processes in acute injuries like spinal cord injuries. Researchers are optimistic that this approach could improve treatment options, making therapies safer and more effective.

 

Research objectives

The GMP laboratory at Paracelsus Medical Private University is uniquely positioned to produce human cells with stem cell-like properties from various tissues under different conditions. Additionally, it can filter and analyze the tiny nanovesicles generated by these cells. Our research goal is to become one of the first institutions worldwide to produce these nanovesicles, known as eNV, as biological medicines for patients under highly controlled conditions.

Equipped with state-of-the-art facilities, the GMP laboratory is well-positioned to participate in early clinical trials for testing eNV. It aims to take a leading role in Europe and beyond in this field. The development of eNV as a biological therapy represents an innovative approach in regenerative medicine. This not only drives significant advancements in scientific research at the Paracelsus Medical Private University but also fosters interdisciplinary collaboration in biomedical science.

 

Contact persons

Mario
Univ.-Doz. Dr. Mario Gimona //
GMP Labor
deputy head of production GMP